Search results for: hospital

European Commission Approves Upadacitinib for Psoriatic Arthritis & Ankylosing Spondylitis

Michele B. Kaufman, PharmD, BCGP | February 4, 2021

In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.

FDA Approves New Rituximab Biosimilar & Anakinra to Treat a Rare Disease

Michele B. Kaufman, PharmD, BCGP | February 2, 2021

The FDA has approved anakinra to treat a rare autoinflammatory disease, deficiency of interleukin 1 receptor antagonist. The administration also approved a new rituximab biosimilar, Riabni, for multiple indications.

Late-Breaking Abstract Session Spans the Realm of Drug-Related Research

Vanessa Caceres | January 25, 2021

In the late-breaking abstract session at ACR Convergence 2020, drug research for a variety of indications is reviewed.

The Psychosocial Toll of COVID-19

Thomas R. Collins | January 25, 2021

Experts discussed the heavy toll the pandemic has taken on patients and clinicians, with many patients in need of mental health support and others in need of rehabilitation.

Smart, Stem Cell-Based Implants May Revolutionize the Treatment of Arthritis

Lara C. Pullen, PhD | January 25, 2021

Recent breakthroughs in stem cell-based treatments for arthritis may help delay joint replacement for some patients. Farshid Guilak, PhD, described the methods for creating bioartificial cartilage, its implications for inflammation, disease flare and more.

Diagnostic Drill-Down: New Research Suggests Genetic Autoinflammatory Roots

Mary Beth Nierengarten | January 25, 2021

Two experts discussed ongoing difficulties in diagnosing autoinflammatory disease, & promising new studies that point to possible genetic roots of autoinflammatory disease.

Denosumab Promising for Osteolysis after Total Hip Replacement

Marilynn Larkin | January 25, 2021

NEW YORK (Reuters Health)—Denosumab showed biological efficacy against osteolysis after total hip replacement in a proof-of-concept trial. “Denosumab is already a well-established licensed drug for the indications of osteoporosis and metastatic bone lesions in cancer, and has been shown to be effective in reducing erosions in inflammatory arthritis,” Dr. Mark J.M. Wilkinson of the University…

Risankizumab May Improve Symptoms of PsA

Michele B. Kaufman, PharmD, BCGP | January 21, 2021

Results from two recent phase 3 clinical trials show risankizumab significantly improved the skin and joint symptoms of patients with psoriatic arthritis compared with placebo.

A Pandemic of Psychological Distress Is Upon Us

Tamar Rubinstein, MD, Natoshia Cunningham, PhD, & Andrea Knight, MD, MSCE | January 20, 2021

It is nine months into the COVID-19 pandemic in the U.S. and the third wave is upon us, overwhelming hospital systems in many states across the country. But the alarms are being sounded for another looming pandemic as well. As early as spring 2020, significant increases were documented in the prevalence of depression and anxiety,…

COVID-19 Vaccines: Implications for Rheumatology Practice & Research

Larry Beresford | January 19, 2021

In late December, the ACR convened a COVID-19 Vaccine Consortium via a conference call to consider rheumatology’s place in the massive worldwide effort to develop, test, deliver and further study the vaccines promising to bring the historic pandemic under control.